Inflammation as a risk factor and target for therapy in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 6, 2011, Pages 662-668

  Miyamoto, Tetsu ^a   Carrero, Juan J ^a,b   Stenvinkel, Peter ^a  

^a Department of Clinical Science Intervention and Technology ^*  (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

C reactive protein; chronic kidney disease; dialysis; inflammation; wasting

Indexed keywords

ACETYLCYSTEINE; ALISKIREN; ALLOPURINOL; ALPHA TOCOPHEROL; APOLIPOPROTEIN E; BARDOXOLONE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCITRIOL; CHOLESTEROL; COLECALCIFEROL; DOCOSAHEXAENOIC ACID; ETANERCEPT; EZETIMIBE; GAMMA TOCOPHEROL; GHRELIN; INTERLEUKIN 6; PENTRAXIN 3; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSUVASTATIN; SEVELAMER; SIMVASTATIN; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; COMPETITIVE INHIBITION; HEMODIALYSIS; HUMAN; IMMUNOMODULATION; INFLAMMATION; MORBIDITY; MORTALITY; MUSCLE ATROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL STATUS; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CALORIE MALNUTRITION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; UREMIA;

ANTIOXIDANTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; PROTEIN-ENERGY MALNUTRITION; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TREATMENT OUTCOME; UREMIA;

EID: 80054726333     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32834ad504     Document Type: Review

References (66)

1. Stenvinkel P, Carrero JJ, Axelsson J, et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3:505-521.
2. Carrero JJ, Stenvinkel P. Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 2009; 4 (Suppl 1):S49-S55.
3. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease: what have we learned in 10 years? Semin Dial 2010; 23:498-509.
4. McIntyre CW, Harrison LE, Eldehni MT, et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:133-141.
5. Meuwese CL, Halbesma N, Stenvinkel P, et al. Variations in C-reactive protein during a single haemodialysis session do not associate with mortality. Nephrol Dial Transplant 2010; 25:3717-3723.
6. Meuwese CL, Stenvinkel P, Dekker FW, et al. Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nat Rev Nephrol 2011; 7:166-176.
7. Meuwese CL, Snaedal S, Halbesma N, et al. Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-a are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant 2011; 26:1313-1318.
8. Kawaguchi T, Tong L, Robinson BM, et al. C-reactive protein and mortality in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephron Clin Pract 2010; 117:c167-c178.
9. Verduijn M, Prein RA, Stenvinkel P, et al. Is fetuin-A a mortality risk factor in dialysis patients or a mere risk marker? A Mendelian randomization approach. Nephrol Dial Transplant 2011; 26:239-245.
10. Contreras G, Hu B, Astor BC, et al. Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol 2010; 21:2131-2142.
11. Carrero JJ, Nakashima A, Qureshi AR, et al. Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney Int 2011; 79:749-756.
12. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med 2010; 268:456-467.
13. Witasp A, Carrero JJ, Heimbürger O, et al. Increased expression of proinflammatory genes in abdominal subcutaneous fat in advanced chronic kidney disease patients. J Intern Med 2010; 77:550-556.
14. Upadhyay A, Larson MG, Guo CY, et al. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant 2011; 26:920-926.
15. Carrero JJ, Ortiz A, Qureshi AR, et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:110-118.
16. Yilmaz MI, Carrero JJ, Mart́in-Ventura JL, et al. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 2010; 5:1174-1181.
17. Yilmaz MI, Sonmez A, Ortiz A, et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol 2011; 6:785-792.
18. Liabeuf S, Barreto DV, Barreto FC, et al. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant 2010; 25:2596-2602.
19. Koc M, Toprak A, Arikan H, et al. Toll-like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis: relation with inflammation. Nephrol Dial Transplant 2011; 26:955-963.
20. Tong M, Carrero JJ, Qureshi AR, et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007; 2:889-897.
21. Suliman ME, Qureshi AR, Carrero JJ, et al. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. QJM 2008; 101:397-405. (Pubitemid 351619248)
22. Dubin R, Shlipak M, Li Y, et al. Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis. Nephrol Dial Transplant 2011; 26:1903-1908.
23. Matsubara J, Sugiyama S, Nozaki T, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 2011; 57:861-869.
24. Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009; 120:699-708.
25. Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 2010; 20:35-40.
26. Raj DS, Carrero JJ, Shah VO, et al. Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. Am J Kidney Dis 2009; 54:1072-1080.
27. Nakashima A, Carrero JJ, Qureshi AR, et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5:2213-2219.
28. Basta G, Leonardis D, Mallamaci F, et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int 2010; 77: 225-231.
29. Lee PS, Sampath K, Karumanchi SA, et al. Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J Am Soc Nephrol 2009; 20:1140-1148.
30. Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluat ing Rosuvastatin) trial. J Am Coll Cardiol 2010; 55:1266-1273.
31. Krane V, Winkler K, Drechsler C, et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 2008; 74:1461-1467.
32. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1395-1407.
33. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238-248. (Pubitemid 41058323)
34. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181-2192.
35. Bobryshev YV. Vitamin D3 suppresses immune reactions in atherosclerosis, affecting regulatory T cells and dendritic cell function. Arterioscler Thromb Vasc Biol 2010; 30:2317-2319.
36. Stubbs JR, Idiculla A, Slusser J, et al. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010; 21:353-361.
37. Matias PJ, Jorge C, Ferreira C, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010; 5:905-911.
38. Marangon N, Lindholm B, Stenvinkel P. Nonphosphate-binding effects of sevelamer: are they of clinical relevance? Semin Dial 2008; 21:385-389.
39. Stinghen AE, Goncalves SM, Bucharles S, et al. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. Blood Purif 2010; 29:352-356.
40. Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 2008; 155:791-805. (Pubitemid 351601744)
41. Yilmaz MI, Axelsson J, Sonmez A, et al. Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol 2009; 4:535-541.
42. Yamamoto D, Takai S, Hirahara I, et al. Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy. Clin Chim Acta 2010; 411:762-764.
43. Morishita Y, Hanawa S, Chinda J, et al. Effects of Aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res 2011; 34:308-313.
44. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5:1388-1393.
45. Wanner C, Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002; 17 (Suppl 8):29-32. (Pubitemid 34918876)
46. Akar H, Coskun Akar G, Carrero JJ, et al. Systemic consequences of poor oral health in chronic kidney disease patients. Clin J Am Soc Nephrol 2011; 6:218-226.
47. Aguilera A, Gonzalez-Espinoza L, Codoceo R, et al. Bowel bacterial overgrowth as another cause of malnutrition, inflammation, and atherosclerosis syndrome in peritoneal dialysis patients. Adv Perit Dial 2010; 26:130-136.
48. Goldstein SL, Ikizler TA, Zappitelli M, et al. Noninfected hemodialysis catheters are associated with increased inflammation compared to arteriovenous fistulas. Kidney Int 2009; 76:1063-1069.
49. Castaneda C, Gordon PL, Parker RC, et al. Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. Am J Kidney Dis 2004; 43:607-616. (Pubitemid 38401875)
50. Bowden RG, Wilson RL, Deike E, et al. Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease. Nutr Clin Pract 2009; 24:508-512.
51. Hung KC, Wu CC, Chen HS, et al. Serum IL-6, albumin and co-morbidities are closely correlated with symptoms of depression in patients on maintenance haemodialysis. Nephrol Dial Transplant 2011; 26:658-664.
52. Don BR, Kim K, Li J, et al. The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin Nephrol 2010; 73:431-438.
53. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-1526. (Pubitemid 46588416)
54. Hung AM, Ellis CD, Shintani A, et al. IL-1 b receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol 2011; 22:437-442.
55. Ramos LF, Kane J, McMonagle E, et al. Effects of combination tocopherols and alpha lipoic acid therapy on oxidative stress and inflammatory biomarkers in chronic kidney disease. J Ren Nutr 2011; 21:211-218.
56. Himmelfarb J, Phinney S, Ikizler TA, et al. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Ren Nutr 2007; 17:296-304. (Pubitemid 47284905)
57. Nascimento MM, Suliman ME, Silva M, et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Perit Dial Int 2010; 30:336-342.
58. Kirmizis D, Papagianni A, Belechri AM, et al. Effects of vitamin E-coated membrane dialyser on markers of oxidative stress and inflammation in patients on chronic haemodialysis. Nephrol Dial Transplant 2011; 26:2296-2301.
59. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011 [Epub ahead of print].
60. Cheema BS, Abas H, Smith BC, et al. Effect of resistance training during hemodialysis on circulating cytokines: a randomized controlled trial. Eur J Appl Physiol 2011; 111:1437-1445.
61. Carrero JJ, Qureshi AR, Nakashima A, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant 2011; 26:184-190.
62. Deboer MD, Zhu X, Levasseur PR, et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 2008; 149:827-835. (Pubitemid 351159354)
63. Miyamoto T, Carrero JJ, Qureshi AR, et al. Circulating fol listati n in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival. Clin J Am Soc Nephrol 2011; 6:1001-1008.
64. Zhang L, Rajan V, Lin E, et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 2011; 25:1653-1663.
65. Cordeiro AC, Qureshi AR, Stenvinkel P, et al. Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant 2010; 25:562-568.
66. Carrero JJ, Cordeiro AC, Lindholm B, et al. The emerging pleiotropic role of adipokines in the uremic phenotype. Curr Opin Nephrol Hypertens 2010; 19:37-42.